Several novel tri-peptide cationic lipids were designed and synthesized for delivering DNA and siRNA. They have tri-lysine and tri-ornithine as headgroups, carbamate group as linker and 12 and 14 carbon atom alkyl groups as tails. These tri-peptide cationic lipids were prepared into cationic liposomes for the study of the physicochemical properties and gene delivery. Their particle size, Zeta potential and DNAbinding were characterized to show that they were suitable for gene transfection. The further results 10 indicate that these lipids can transfer DNA and siRNA very efficiently into NCI-H460 and Hep-2 tumor cells. The selected lipid, CDO14, was able to deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in lung tumors of mice, with little in vitro and in vivo toxicity.
Introduction a
Viral vectors and non-viral vectors are widely used to modulate 15 gene expression in target tissues to correct genetic defects for gene therapeutic application. Viral vectors, such as adenovirus vectors, adeno-associated virus vectors, or retrovirus vectors, have been applied in clinical trials. [1] [2] [3] However, some side effects including immunoresponse and infection have been reported. 4-5 20 Non-viral gene delivery systems have, on one hand, been demonstrated as standard tools for in vitro transfection with many commercially available kits. [6] [7] [8] On the other hand, they are regarded as a promising approach for the treatment of genetic diseases and cancers. 9-12 25 Among these non-viral vectors, peptide cationic lipids have drawn great attention, [13] [14] [15] [16] [17] [18] as peptides are more biocompatible. Peptides and their derivatives have been used for restraining cancer cell migration, curing anti-thrombosis, treating acute renal failure, reducing anti-inflammation and promoting skin 30 regeneration, etc. But the isolated small peptides are easily degraded by enzymes in vivo, and they could be cleared very quickly. [19] [20] People found that the introduction of peptide groups into lipids can prolong their half-life in vivo and enhance targeting thereof. gene therapeutics. [22] [23] [24] However, the current peptides based cationic lipids still hold some limitations.
25-26 Therefore, we designed and synthesized a series of novel tri-peptide cationic lipids CDL12, CDL14, CDO12 and CDO14 ( Fig. 1) for facilitating the use of peptides based lipids for gene delivery. and anti-luciferase siRNA were purchased from Sigma-Aldrich (USA). 1,2-Dioleoyl-3-trimethylammoniumpropane (DOTAP) was purchased from Roche Shanghai (China). Hep-2 and NCI-H460 cells were purchased from the Institute of Biochemistry and Cell Biology (China). A549 cells were from Leaf's lab of the 20 University of North Carolina at Chapel Hill. DMEM, RPMI1640, fetal bovine serum (FBS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Gibco (USA). Green fluorescent protein (pGFP-N2) and luciferase (pGL3) plasmid vectors were purchased from Sangon Biotech Co. 25 Ltd. (China), and extracted in our lab. Bright-Glo™ Luciferase Assay System was purchased Promega Biotech Co. Ltd. (Beijing, China). All other chemicals were of reagent grade.
Synthesis of lipids
The synthesis of these lipids was performed as follows, using 30 CDL12 as an example (Scheme 1): CDI was added to lauryl alcohol in toluene and kept at reflux for 3 h. Diethylenetriamine was added. After another 3 h, the solvent was evaporated. The crude product was recrystallised from the mixture solvent of ethanol/water to give intermediate 1. recrystallised from the mixed solvent of acetonitrile and petroleum ether to give white crystal as CDL12. 1 H and 13 C NMR spectra were measured at 400 and 100 MHz, respectively, on a Varian MercuryPlus 400 spectrometer. High 55 resolution electrospray ionization mass spectrometry was performed using a Q-Tof Micro (Micromass Inc., Manchester, UK). IR spectra were recorded using an IRPrestige-21 (Shimadzu, JAPAN). HPLC was performed on a LC-20AB (Shimadzu, JAPAN) with a C18 column, 1% TFA in 60 methanol/water mobile phase (85:15), the flow rate of 0.8 mL/min.
Chemical analysis of lipids

Preparation and characterisation of liposomes
The protocol for preparation of liposomes based on CDL12, CDL14, CDO12 and CDO14 lipids was optimised to obtain high-65 quality delivery systems. The lipids were formulated in combination with the neutral lipid DOPE in 1:1 molar ratio. To prepare liposomes, a suitable amount of lipid and DOPE were dissolved in 1 mL of chloroform in a 5 mL glass vial. The solvent was removed under a stream of nitrogen gas, followed by high-70 vacuum desiccation. The dry lipid film was resuspended in 1 mL 
Particle size and Zeta potential measurements
The particle size and Zeta potential were measured with a Malvern ZetaSizer Nano series (Westborough, MA) at room temperature. All the lipoplexes of varying N/P ratios ranging 10 from 1 to 8 were prepared with pGL3 plasmid. For the measurement of particle size and Zeta potential, 20 µL of the liposomes or lipoplexes were diluted to 1 mL with distilled water.
Agarose gel retardation assay
The lipoplexes of varying N/P ratios ranging from 0 to 8 were 15 prepared with pGL3 plasmid. The lipoplexes were electrophoresed in 1.2 % agarose gel containing GelRed and Trisacetate (TAE) running buffer at 90 V for 40 min. DNA bands were visualised in a gel documentation unit (Syngene, Britain).
In vitro pDNA transfection 20 Hep-2 and NCI-H460 cells were seeded in 24-well plates (5.0 × 10 4 cells/well), and incubated at 37 ºC under 5 % CO 2 until approximately 80 % confluence was attained. The medium was removed and replaced with 100 µL serum-free DMEM per well. Cationic liposome/DNA lipoplexes were then added to the plates 25 and incubated for 4 h at 37 ºC. The medium was then replaced with DMEM containing 10 % FBS and 1 % antibiotics, and the cultures were maintained at 37 ºC under 5 % CO 2 for 48 h.
The expression of green fluorescent protein was measured using an inverted fluorescence microscope (Olympus IX71, 30 Japan). Relative luciferase activity was assessed using a BrightGlo TM Luciferase Assay System and Synergy TM 2 MultiDetection Microplate Reader. Briefly, the growth medium was removed from each well, and luciferase activity was measured after lysis buffer was added. The total protein concentration in the 35 cell lysate was measured using a BCA protein assay kit and luciferase activity was expressed as relative light units (RLU) per mg protein.
In vitro siRNA transfection A549 cells expressing firefly luciferase were seeded in 12-well 40 plates (1.0 × 10 5 per well) approximately 24 h before experiments. Cells were treated with different lipid formulations at the anti-luciferase siRNA concentration of 40 nM in Opti-MEM at 37 ºC for 4 h. Cells were washed with DPBS, followed by incubation with lysis buffer at room temperature for 20 min. 45 Fluorescence intensity in cell lysate was determined using a Perkin-Elmer LS 50B luminescence spectrometer (Norwalk, CT) (λ ex , 494 nm; λ em , 519 nm). Cell lysate (5 µg per well) was dissolved in BCA protein assay reagent, and total protein concentrations determined at 570 nm. The silencing rate is 50 expressed as relative light units (RLU) per microgram of total protein.
Cytotoxicity of the cationic liposomes
The assay was performed in 96-well plates by maintaining the N/P weight ratios as used in the transfection experiments. The 55 cells were seeded in 96-well plates and incubated at 37 ºC under 5 % CO 2 for 24 h to get a confluence of about 80 %. After the replacement of medium, the liposomes/DNA complexes were added to the cells for further culture at 37 ºC under 5 % CO 2 for 24 h, and then MTT (20 µL, 5 mg/mL) was added and kept for 60 4.5 h. The absorbance at 570 nm was monitored by using the enzyme mark instrument (Sunrise Tecan, Australia).
Animals
In vivo studies were carried out on BALB/c nude mice of age 4-6 weeks. All experiments performed on the animals were in 65 accordance with and approved by the Institutional Animal Care and Use Committee at University of North Carolina.
In vivo gene silencing study
Combined siRNAs against c-Myc and VEGF (1:1) were codelivered by CDO14 liposome. The tumor-bearing mice were 70 injected IV times every 3 days via tail vein with lipoplexes at the N/P ratio of 3:1 (with a dose of 0.45 mg total siRNA/kg). One day after the third injection, the mice were killed and the tumorloaded lungs were collected for the preparation of paraffin embedded sections (4-5 µm thick). Expressions of c-Myc and 75 VEGF in the sections were examined immunohistochemically using the antibodies from a kit in accordance with the product protocol.
TUNEL assay
TUNEL staining was performed as recommended by the 80 manufacturer's protocol (Promega, Madison, WI). Tumorbearing mice were given i.v. injections of the siRNA formulated in the CDO14 on days 9 and 10. Twenty-four hours after the second injection, the mice were killed, and the tumor-loaded lungs were collected for the TUNEL staining. The nuclei were 85 counterstained with hematoxylin, and the samples were imaged using an inverted fluorescence microscope (Olympus IX71, Japan).
Toxicity of the cationic liposomes in vivo
The tumor-bearing mice were i.v. injected with siRNA 90 formulated in the targeted liposome at 3:1 doses, and the serum cytokine level was determined with Olympus AU400 Automatic Biochemistry Analyzer. Mouse body weight was also monitored.
Statistical analysis
The data were presented as mean values ± SD. The statistical 95 significance was determined using two-way analysis of variance. P values <0.05 were considered significant.
Results and discussion
Design and synthesis of cationic lipids
The tri-peptide cationic lipids designed are composed of three 100 biocompatible molecular moieties: tri-lysine peptides or triornithine peptides (the cationic headgroup), carbamate (the linker), and two hydrocarbon chains (hydrophobic tails). These tri-peptide cationic lipids were prepared by adapting a straight forward procedure (Scheme 1 The structures and purities of tri-peptide cationic lipids were characterised by electrospray ionisation-mass spectrometry (ESI-10 MS), proton nuclear magnetic resonance spectroscopy ( 1 H NMR, 13 C NMR), infrared (IR) spectroscopy, and high pressure liquid chromatography (HPLC) (Fig. S1-S4, ESI †) . The analytical data of these compounds are listed under the figures in the ESI † to show that tri-peptide cationic lipids were successfully obtained. 15 
Particle size, and Zeta-potential of tri-peptide cationic liposomes and lipoplexes
Our previous study showed that liposomes had higher transfection efficiency with equivalent molar ratio of DOPE, so the liposomes were prepared by using the tri-peptides with DOPE 20 as co-lipid at a molar ratio of 1:1. The dynamic light scattering showed the particle sizes of these liposomes were from 70 nm to 150 nm, those for the lipoplexes of CDO14/DNA were from 200 nm to 400 nm in the N/P ratio range from 1:1 to 8:1 (Fig. 2, 3 ). Zeta potentials of liposomes were between 40-60 mV, which 25 ensured the stability of the liposomes for at least three months. Zeta potentials of the lipoplexes of CDO14/DNA were found to increase from -50 mV to nearly 0 mV with the increase of the N/P ratios from 1:1 to 8:1 (Fig. 2, 3) . The sizes and Zeta potentials were in the ranges suitable for gene transfection. 27 The 45 morphological characteristics were directly visualised by transmission electron microscopy (TEM) (Fig. S5 , ESI †). Images obtained from CDO14 liposome and CDO14 liposome/DNA lipoplex at the N/P ratio of 3:1 revealed well-defined spherical structures.
50
DNA-binding assay
DNA-binding with liposomes is a key factor for gene transfection. 28 Therefore, the electrostatic binding interactions between plasmid DNA and the tri-peptide cationic liposomes were measured by the gel retardation assay across the N/P ratios 55 of 0:1-8:1. Findings in the gel retardation assay revealed all the liposomes could start to retard the plasmid DNA at the N/P ratio of 0.5:1. They could nearly completely retard pDNA at higher N/P ratios of 6:1, 6:1, 6:1 and 3:1 for CDL12, CDL14, CDO12 and CDO14, respectively. Though all the above liposomes could 60 bind pDNA at higher N/P ratios, the lower N/P ratio of CDO14 for retardation compared with other liposomes may reduce its dose required to obtain maximal transfection efficiency. The above results demonstrate that cationic liposomes can form DNA- 
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liposomes complexes at different N/P ratios. This ensured the entry of pDNA into cells and the protection of pDNA from degradation by DNase. (Fig. S6, ESI †) .
In vitro pDNA and siRNA transfection targeting siRNA-peptide lipid complexes at the N/P ratio of 3:1 (the amount of pGL3 was 0.5 µg/well, 96-well plates). Statistical analysis was accomplished by a two-way ANOVA: *, P < 0.05; **, P < 0.01.
undergo the following process. First, the plasmid DNA binds to 40 the tri-peptide head-groups of the cationic lipids. Then, the lipids/DNA lipoplexes will enter the Hep-2 cells and NCI-H460 cells (e.g., via endocytosis), and trypsin in the cell will hydrolyze the carbamate bond in the lipids. The hydrolization assists DNA to escape from the endosome for the subsequent transcription.
45
The whole process is readily performed and thus enhances DNA transfection efficiency. Tri-peptide lipids were screened for the ability to deliver siRNA to A549 lung carcinoma cells which can stably express firefly luciferase (Fig. 6) . The efficacy of siRNA delivery by 50 these tri-peptide lipids was determined by treating cells with siRNA-complexes, prepared using a firefly luciferase targeting siRNA(siLuc). [29] [30] Overall, all four lipids showed gene silence compared with the control. Three of them were better than DOTAP, and CDO14 and CDL14 were slightly better than 55 Lipofectamine 2000, silencing nearly 75 % of luciferase in A549 cells. Much work has been carried out on modifying cationic lipids for use in gene transfection, to determine if there is a 'best' chain length. 31 However, solid conclusions are rarely obtained, for the conclusions of these studies are frequently contradictory.
60
In this study, CDL14 and CDO14 showed superior siRNA delivery. It may maintain an appropriate balance between fluidity and rigidity for entering into cells, and have the ability to release siRNA in cells due to the carbamate linker.
Cytotoxicity of the cationic liposomes
65
Cytotoxicity of gene delivery materials could be measured by the MTT method. Cell viabilities after exposure to lipids, CDL12, CDL14, CDO12 and CDO14, were evaluated in NCI-H460 cells and Hep-2 cells across the entire range of N/P weight ratios used in the transfection experiments. Cells could tolerate all the lipids 70 at relatively low N/P ratios (under 4:1), better than the commercial liposomes, Lipofectamine 2000 and DOTAP (Fig. 7) . The lower cytotoxicity of these lipids should be contributed to the nature of the peptide headgroups, as they are more biocompatible over quaternary ammonium with cells, thus increasing the toleration of cells to them.
19, 24
In vivo gene silencing study Since cationic lipid CDO14 showed optimal in vitro pDNA and indicate that the combined siRNAs formulated in CDO14 liposome were able to simultaneously silence the expressions of the target oncogenes in the lung tumors. The successful interference of combined siRNAs to different genes opens a door 35 by silencing multi-oncogenic pathways by using tri-peptide cationic lipids. This increases the possibility of CDO14 as a potential candidate for the further in vivo study and clinical trials.
TUNEL assay
Apoptotic induction plays an essential role in the suppression of 40 tumor cell proliferation. 33 We examined the apoptosis induced by siRNAs using the TdT dUTP nick end-labeling (TUNEL) staining (Fig. 9) . As shown in the figure, the number of TUNELpositive cells increased after intravenous injections of siRNA formulated in CDO14 liposome. Intravenous injections of siRNA 45 in the control group showed only a slight increase in TUNELpositive cells. No significant apoptotic induction was observed in other treatment groups. These results suggest that this formulation triggered cell death and might play a critical role in regulating the survival of A549 lung cancer cells in vivo.
50
Toxicity of the cationic liposomes in vivo
In addition to therapeutic effect, toxicity is a crucial parameter of a therapeutic agent for clinical use. At the therapeutic dose (0.45 mg/kg), the formulation did not induce significant elevation of renal indicators and liver enzymes, including blood urea nitrogen 55 (BUN), creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ( Table 1) . Additionally, the body weights of mice were stably increased after post injection of lipoplexes at the therapeutic dose (Fig. 10) Therefore, the toxicity of cationic lipids is mainly determined by their cationic nature. The replacement of quaternary ammonium with tri-peptide increased the affinity and biocompatibility, 10 thereby, increasing their transfection and lowering toxicity.
Conclusion
In summary, we selected the tri-peptide Lys-Lys-Lys and OrnOrn-Orn as the headgroups for the gene delivery study, because both lysine and ornithine are found in a number of structurally 15 characterized DNA binding domains of proteins. These cationic lipids are relatively simple to synthesize by using standard peptide chemistry, and their chemical structures can readily be tailored for effective interaction with DNA. The in vitro delivery results of pDNA and siRNA by these tri-peptide lipids against 20 NCI-H460 and Hep-2 tumor cells show that they could lead to superior transfection compared to conventional non-viral transfection reagents. They also showed lower cytotoxicity against the two tumor cells. The lipid CDO14 with ornithine as headgroup and 14 carbon atom alkyl groups at tails demonstrated 25 better transfection over other lipids. It was selected to be used for in vivo evaluation. It showed not only enhanced transfection activity, but also very low toxicity in vivo. CDO14 could be able to deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in lung tumors of mice. 30 The results of this study strengthen the validity of the peptides based cationic lipids as a drug delivery vehicle for cancer therapy. 
